Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 10/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17108610 | 1.00 | CASP1 (0.38) | CASP1ALDH1A1CYP3A4HSD17B10TSHR | |
| SCHEMBL17108608 | 1.00 | CASP1 (0.38) | CASP1ALDH1A1CYP3A4HSD17B10TSHR | |
| SCHEMBL18760199 | 0.88 | ALDH1A1 (0.32) | CASP1ALDH1A1MAPTKDM4EMAPK1 | |
| SCHEMBL17108619 | 0.85 | SYK (0.40) | CASP1ALDH1A1CYP3A4HSD17B10MAPT | |
| SCHEMBL18748453 | 0.83 | CASP1 (0.48) | CASP1ALDH1A1CYP3A4HSD17B10TSHR | |
| SCHEMBL17101248 | 0.80 | HPGD (0.45) | ALDH1A1TSHRMAPTKDM4EGAA | |
| SCHEMBL17108598 | 0.80 | SYK (0.42) | ALDH1A1HSD17B10MAPK1KMT2ALMNA | |
| SCHEMBL17108605 | 0.79 | CTSA (0.44) | ALDH1A1CYP3A4HSD17B10MAPTKDM4E | |
| SCHEMBL20146223 | 0.74 | ERN1 (0.47) | CASP1ALDH1A1CYP3A4MAPTKMT2A | |
| SCHEMBL17101442 | 0.71 | HPGD (0.50) | ALDH1A1MAPTKDM4EGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954211-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-23 | — | — | US | disclosed |
| CN-106103423-B | Pyrazine compounds | 阿斯利康(瑞典)有限公司 | 2019-12-06 | — | — | CN | disclosed |
| US-20190330187-A1 | Chemical Compounds | ASTRAZENECA UK LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| EP-3119752-B1 | 3,4-DIAMINO-6-CHLOROPYRAZINE-2-CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF ENAC MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954211-B2 | Chemical compounds | CFTR, SCNN1B, SCNN1A | CASP1 3276/4885ALDH1A1 933/4885CYP3A4 2450/4885 |
| US-20190330187-A1 | Chemical Compounds | CFTR, SCNN1B, SCNN1A | CASP1 3276/4885ALDH1A1 933/4885CYP3A4 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.